Development and validation of the Michigan Chronic Disease Simulation Model (MICROSIM).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 09 01 2023
accepted: 19 02 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 16 5 2024
Statut: epublish

Résumé

Strategies to prevent or delay Alzheimer's disease and related dementias (AD/ADRD) are urgently needed, and blood pressure (BP) management is a promising strategy. Yet the effects of different BP control strategies across the life course on AD/ADRD are unknown. Randomized trials may be infeasible due to prolonged follow-up and large sample sizes. Simulation analysis is a practical approach to estimating these effects using the best available existing data. However, existing simulation frameworks cannot estimate the effects of BP control on both dementia and cardiovascular disease. This manuscript describes the design principles, implementation details, and population-level validation of a novel population-health microsimulation framework, the MIchigan ChROnic Disease SIMulation (MICROSIM), for The Effect of Lower Blood Pressure over the Life Course on Late-life Cognition in Blacks, Hispanics, and Whites (BP-COG) study of the effect of BP levels over the life course on dementia and cardiovascular disease. MICROSIM is an agent-based Monte Carlo simulation designed using computer programming best practices. MICROSIM estimates annual vascular risk factor levels and transition probabilities in all-cause dementia, stroke, myocardial infarction, and mortality in a nationally representative sample of US adults 18+ using the National Health and Nutrition Examination Survey (NHANES). MICROSIM models changes in risk factors over time, cognition and dementia using changes from a pooled dataset of individual participant data from 6 US prospective cardiovascular cohort studies. Cardiovascular risks were estimated using a widely used risk model and BP treatment effects were derived from meta-analyses of randomized trials. MICROSIM is an extensible, open-source framework designed to estimate the population-level impact of different BP management strategies and reproduces US population-level estimates of BP and other vascular risk factors levels, their change over time, and incident all-cause dementia, stroke, myocardial infarction, and mortality.

Identifiants

pubmed: 38753617
doi: 10.1371/journal.pone.0300005
pii: PONE-D-23-00713
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0300005

Informations de copyright

Copyright: © 2024 Burke et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

James F Burke (JF)

Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.

Luciana L Copeland (LL)

Independent Software Developer, Ann Arbor, MI, United States of America.

Jeremy B Sussman (JB)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.
Institute for Healthcare Policy and Innovation, U-M, Ann Arbor, MI, United States of America.
Ann Arbor Veteran's Affairs Hospital, Center for Clinical Management and Research, Ann Arbor, MI, United States of America.

Rodney A Hayward (RA)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.
Institute for Healthcare Policy and Innovation, U-M, Ann Arbor, MI, United States of America.
Ann Arbor Veteran's Affairs Hospital, Center for Clinical Management and Research, Ann Arbor, MI, United States of America.

Alden L Gross (AL)

Department of Epidemiology, Johns Hopkins Bloomberg School Public Health, Baltimore, MD, United States of America.

Emily M Briceño (EM)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.
Department of Physical Medicine and Rehabilitation, U-M, Ann Arbor, MI, United States of America.

Rachael Whitney (R)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.

Bruno J Giordani (BJ)

Department of Psychiatry & Michigan Alzheimer's Disease Center, U-M, Ann Arbor, MI, United States of America.

Mitchell S V Elkind (MSV)

Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States of America.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States of America.

Jennifer J Manly (JJ)

Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States of America.
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, United States of America.

Rebecca F Gottesman (RF)

Stroke Branch, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, United States of America.

Darrell J Gaskin (DJ)

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.

Stephen Sidney (S)

Kaiser Permanente Northern California Division of Research, Oakland, CA, United States of America.

Kristine Yaffe (K)

Departments of Psychiatry, Neurology and Epidemiology, University of California, San Francisco, San Francisco, CA, United States of America.

Ralph L Sacco (RL)

Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, United States of America.

Susan R Heckbert (SR)

Department of Epidemiology, University of Washington, Seattle, WA, United States of America.

Timothy M Hughes (TM)

Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.

Andrzej T Galecki (AT)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.
Department of Biostatistics, U-M, Ann Arbor, MI, United States of America.

Deborah A Levine (DA)

Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan (U-M), Ann Arbor, MI, United States of America.
Institute for Healthcare Policy and Innovation, U-M, Ann Arbor, MI, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH